연구동향 분석

The force awakens: metastatic dormant cancer cells

So-Yeon Park 남정석 2020년

논문상세정보
    • 저자 So-Yeon Park 남정석
    • 제어번호 107230715
    • 학술지명 Experimental and molecular medicine
    • 권호사항 Vol. 52 No. - [ 2020 ]
    • 발행처 생화학분자생물학회
    • 자료유형 학술저널
    • 수록면 1-13
    • 언어 English
    • 출판년도 2020
    • 등재정보 KCI등재
    • 판매처
    유사주제 논문( 0)
인용/피인용

' The force awakens: metastatic dormant cancer cells' 의 참고문헌

  • β1-integrin : a potential therapeutic target in the battle against cancer recurrence
    Barkan, D. [2011]
  • Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin : a phase I, pharmacokinetic, and biological correlative study
  • Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo
  • Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
    Lan, Q. [2019]
  • Tumor‐reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells
  • Tumor metastasis : molecular insights and evolving paradigms
    Valastyan S [2011]
  • Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
  • Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma
    Eyles, J. [2010]
  • Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells?
  • The role of cellular reactive oxygen species in cancer chemotherapy
    Yang, H. [2018]
  • The relationship between dormant cancer cells and their microenvironment
    Linde, N. [2016]
  • The inherent premise of immunotherapy for cancer dormancy
  • Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction
  • TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling
    Bragado, P. [2013]
  • TGF-β-induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma
  • TGF-β family signaling pathways in cellular dormancy
    Prunier, C. [2018]
  • T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells
  • Significance of monocyte counts at recurrence on survival outcome of women with endometrial cancer
    Machida, H. [2017]
  • Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors
  • STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma : results of a phase 1b trial
  • Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies
  • Reactive oxygen species in cancer
    Liou GY [2010]
  • Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed
  • Randomized phase II trial of sulindac for lung cancer chemoprevention
  • Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non–small-cell lung cancer with cyclooxygenase-2 overexpression : CALGB 30801(Alliance)
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
    Alva, A. [2012]
  • Phase II study of E7820 in combination with cetuximab in subjects(pts)with metastatic and refractory colorectal cancer(CRC)
    Sawyer, M. [2010]
  • Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat(WX-671)in combination with gemcitabine compared with gemcitabine alone in patients with nonresectable, locally advanced pancreatic cancer
  • Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
    Ogura, M. [2015]
  • Phase I study of E7820, an oral inhibitor of integrin α-2expression with antiangiogenic properties, in patients with advanced malignancies
    Mita, M. [2011]
  • Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription(STAT)3 inhibitor, in patients with refractory solid malignancies
    Wong, A. [2015]
  • Phase 2 study of the focal adhesion kinase inhibitor defactinib(VS-6063)in previously treated advanced KRAS mutant non-small cell lung cancer
  • Phase 1/2 study of pacritinib, a next generation JAK2/FLT3inhibitor, in myelofibrosis or other myeloid malignancies
  • Phase 1/1b study of the FAK inhibitor defactinib(VS-6063)in combination with weekly paclitaxel for advanced ovarian cancer
  • Phase 1 trial of the antiangiogenic peptide ATN-161(Ac-PHSCN-NH 2), a beta integrin antagonist, in patients with solid tumours
  • Perivascular M2 macrophages stimulate tumor relapse after chemotherapy
    Hughes, R. [2015]
  • Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
  • NSAID use reduces breast cancer recurrence in overweight and obese women : role of prostaglandin–aromatase interactions
  • Multiple targets of the canonical WNT/beta-catenin signaling in cancers
  • Multifaceted role of the urokinase-type plasminogen activator(uPA)and its receptor(uPAR) : diagnostic, prognostic, and therapeutic applications
    Mahmood, N. [2018]
  • Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling
    Gao, H. [2016]
  • Molecular pathways : MERTK signaling in cancer
  • Modulation of the tumor cell phenotype by IFN-γ results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes
  • Microenvironmental regulation of tumour angiogenesis
  • Metastatic latency and immune evasion through autocrine inhibition of WNT
    Malladi, S. [2016]
  • Metastatic growth from dormant cells induced by a col-I–enriched fibrotic environment
    Barkan, D. [2010]
  • Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis
  • Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs
    Chen, Q. [2011]
  • MAPK signal pathways in the regulation of cell proliferation in mammalian cells
    Zhang, W. [2002]
  • MAP kinase signalling pathways in cancer
  • M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation
    Okubo, M. [2016]
  • Interleukin‐6 predicts recurrence and survival among head and neck cancer patients. Cancer: Interdisciplinary International
  • Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs
    Shibue, T. [2009]
  • Innate and acquired immune surveillance in the postdissemination phase of metastasis
  • Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
    Barkan, D. [2008]
  • Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow : a Reference to early systemic disease in solid cancer
  • Immunemediated dormancy : an equilibrium with cancer
    Teng, M. W. [2008]
  • Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
    Wang, H. [2019]
  • IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse
  • How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
    Mebratu, Y. [2009]
  • GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche
  • Functional coupling of p38-induced up-regulation of BiP and activation of RNAdependent protein kinase–like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells
  • Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases
  • ERK1/2 and p38α/β signaling in tumor cell quiescence : opportunities to control dormant residual disease
    Sosa, M. S. [2011]
  • ERK(MAPK)activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK)
  • ERK implication in cell cycle regulation
  • EMT and dissemination precede pancreatic tumor formation
    Rhim, A. D. [2012]
  • EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma
    Liu, D. [2002]
  • Distant relations : macrophage functions in the metastatic niche
    Doak, G. R. [2018]
  • Differential effect on bone lesions of targeting integrins : randomized phase II trial of abituzumab in patients with metastatic castrationresistant prostate cancer
    Hussain, M. [2016]
  • Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence
    Adam, A. P. [2009]
  • Chronic inflammation and breast cancer recurrence
    Cole, S. W. [2009]
  • Cancer invasion and the microenvironment : plasticity and reciprocity
    Friedl, P. [2011]
  • Cancer dormancy : a regulatory role for endogenous immunity in establishing and maintaining the tumor dormant state
  • CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
    Qian BZ [2011]
  • C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery
    Toiyama, Y. [2013]
  • Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
    Kobayashi A [2011]
  • Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow
    Yumoto, K. [2016]
  • Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy
  • Adaptive Stress Responses During Tumor Metastasis and Dormancy
    Senft D [2016]
  • Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial)
    Coombes, R. [2018]
  • Abstract C119 : Investigation of the anti-angiogenic effects of abituzumab in patients with colorectal or ovarian cancer and liver metastases using dynamic contrast-enhanced magnetic resonance imaging(DCEMRI), AACR-NCI-EORTC
  • Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer : the randomised phase I/II POSEIDON trial
    Elez, E. [2015]
  • ATF6α-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo
  • A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins(intetumumab)in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
  • A randomised, phase II study of intetumumab, an anti-α vintegrin mAb, alone and with dacarbazine in stage IV melanoma
    O’day, S. [2011]
  • A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
    Mak, G. [2019]
  • A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients:Randomized European Celecoxib Trial (REACT)
    Coombes, R. [2011]
  • A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
  • A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3(avb3)integrin, ±dacarbazine(DTIC)in patients with metastatic melanoma(MM)
    Hersey, P. [2005]
  • A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma(PDAC)(MOBILITY-002 Trial, NCT02428270)
    Aung, K. L. [2018]
  • A phase II study of celecoxib with irinotecan, 5-fluorouracil, and leucovorin in patients with previously untreated advanced or metastatic colorectal cancer
    Chen, E. Y. [2018]
  • A phase I-II study of ruxolitinib(INCB18424)for patients with chronic myeloid leukemia with minimal residual disease while on therapy with imatinib
  • A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
  • A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α 2 integrin inhibitor E7820 in patients with advanced solid tumors
  • A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
  • A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
    Sweet, K. [2018]